Preferred Label : Evusheld;
Origin ID : M000753805;
Related record
https://ansm.sante.fr/tableau-acces-derogatoire/tixagevimab-150-mg-cilgavimab-150-mg-solution-injectable-evusheld
2023
false
false
false
France
French
summary of product characteristics
package leaflet
cilgavimab and tixagevimab drug combination
Evusheld
drug combinations
cilgavimab
tixagevimab and cilgavimab
tixagevimab
COVID-19
COVID-19
adult
adolescent
Post-Exposure prophylaxis
risk factors
guidelines for drug use
immunologic deficiency syndromes
injections, intramuscular
SARS Coronavirus 2 B.1.1.529
SARS-CoV-2 variants
---
https://sante.gouv.fr/IMG/pdf/annexe_1_-_dgs_urgent_2023-05.pdf
2023
France
public health guidelines
Paxlovid
effects of exposure to external cause, nos
target population
judgment
health services needs and demand
population groups
Pre-Exposure Prophylaxis
prophylactic treatment, nos
Evusheld
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1176
2022
false
false
false
France
COVID-19
public health guidelines
Evusheld
prophylactic treatment, nos
judgment
Pre-Exposure Prophylaxis
effects of exposure to external cause, nos
---
https://www.inesss.qc.ca/covid-19/traitements-specifiques-a-la-covid-19/tixagevimab-/-cilgavimab-evusheld-en-prophylaxie-preexposition.html
2022
false
false
false
Canada
COVID-19
drug evaluation
Pre-Exposure Prophylaxis
cilgavimab and tixagevimab drug combination
prophylactic treatment, nos
cilgavimab
Evusheld
tixagevimab
---
https://www.has-sante.fr/jcms/p_3352197/fr/evusheld-tixagevimab/cilgavimab-covid-19
2022
false
false
false
France
cilgavimab
tixagevimab
treatment outcome
insurance, health, reimbursement
drug combinations
antiviral agents
Pre-Exposure Prophylaxis
adult
adolescent
immunocompromised host
injections, intramuscular
tixagevimab and cilgavimab
evaluation of the transparency committee
Evusheld
COVID-19
cilgavimab and tixagevimab drug combination
---
https://recalls-rappels.canada.ca/fr/avis-rappel/evusheld-tixagevimab-et-cilgavimab-injectables-risque-echec-prophylaxie-ou-du
2022
false
false
false
Canada
French
English
pharmacovigilance note
canada
drug resistance, viral
cilgavimab and tixagevimab drug combination
drug combinations
tixagevimab
cilgavimab
tixagevimab and cilgavimab
antibodies, monoclonal
antiviral agents
Evusheld
injections, intramuscular
COVID-19
COVID-19
Pre-Exposure Prophylaxis
SARS-CoV-2 variants
---
https://www.has-sante.fr/jcms/p_3383238/fr/evusheld-tixagevimab/cilgavimab-covid-19-adultes-et-adolescents
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intramuscular
antiviral agents
cilgavimab
tixagevimab
drug combinations
tixagevimab and cilgavimab
package leaflet
summary of product characteristics
guidelines for drug use
evaluation of the transparency committee
adolescent
COVID-19
adult
Evusheld
cilgavimab and tixagevimab drug combination
---
https://ansm.sante.fr/actualites/traitements-contre-le-covid-19-les-conditions-dacces-et-dutilisation-devusheld-evoluent
2022
false
false
false
France
French
guidelines for drug use
COVID-19
Evusheld
cilgavimab and tixagevimab drug combination
adult
adolescent
immunocompromised host
Pre-Exposure Prophylaxis
COVID-19
SARS-CoV-2 variants
SARS-CoV-2 Omicron variant infection
SARS Coronavirus 2 B.1.1.529
---
https://www.has-sante.fr/jcms/p_3324748/fr/evusheld-tixagevimab/cilgavimab-150-mg-/-150-mg
2022
false
false
false
France
COVID-19
Pre-Exposure Prophylaxis
Evusheld
cilgavimab and tixagevimab drug combination
adult
adolescent
treatment outcome
insurance, health, reimbursement
drug combinations
cilgavimab
tixagevimab
antiviral agents
guidelines for drug use
evaluation of the transparency committee
---
https://sante.gouv.fr//IMG/pdf/dgs-u_2022_49_-_evusheld.pdf
2022
false
false
false
France
COVID-19
guideline
tixagevimab
monoclonal antibody
tixagevimab
antibodies, monoclonal
Monoclonal antibodies
Evusheld
laboratories
patient care management
Monoclonal antibodies
---
